The National Bleeding Disorders Foundation (NBDF) is alerting the community to updated information from Takeda Pharmaceutical Company regarding the discontinuation timelines for HEMOFIL® M and RECOMBINATE®, two therapies used to treat hemophilia A, first announced last year.
Takeda recently shared a timeline on how long these treatments will remain available for patients currently using them. In a letter to patients, the company stated that HEMOFIL® M will be supplied through September 2026. RECOMBINATE® will remain available through September 2026, with select vial sizes (250 IU and 2000 IU) expected to continue through March 2027.
Takeda emphasized that the decision to discontinue both therapies is not related to safety or efficacy concerns. Patients who currently rely on these treatments are encouraged to speak with their healthcare provider or hemophilia treatment center to discuss alternative therapy options that best meet their individual needs.
NBDF continuously monitors changes in treatment options, healthcare policies, medication recalls, and access issues that may impact your care. To ensure you receive these critical updates as they happen, we encourage you to join NBDF’s mailing list.
NBDF does not provide medical advice or engage in the practice of medicine. NBDF does not endorse or recommend specific treatments for individuals. We strongly encourage all individuals to consult their physician or local treatment center before making any medical decisions or pursuing any course of treatment.
